The o2h human health EIS Fund, is excited to announce an investment into Spirea, a University of Cambridge Biotechnology spin out that is developing the next generation of game changing antibody drug conjugates (ADC) to transform cancer treatment and drastically improve the lives of patients. Spirea has developed a proprietary platform technology, ShieldLink, that may lead to novel ADCs with enhanced ability to treat patients safely and effectively.
Sunil Shah, CEO at o2h ventures, said: “There is a significant interest in ADC’s, as seen by Merck’s recent $2.75B VelosBio acquisition for their ROR1 antibody drug conjugate. We believe that this platform has potential to develop more effective and safer ADC’s and could lead to a series of co-development opportunities with big pharma”.
Dr Myriam Ouberai, CEO of Spirea, said: “We are delighted to have attracted seed funding from o2h ventures. This investment and their support serve as endorsements of our approach and will allow us to optimise and validate our technology.”
About o2h ventures:
The o2h human health EIS Fund is the first S/EIS fund in the UK solely focused on investing in EIS and/or SEIS seed stage companies covering novel drug discovery & AI, digital therapeutics and enabling services.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit www.o2hventures.com